LLY
767.18
+1.35%↑
UNH
499.86
+2.58%↑
NVO
85.05
-17.85%↓
JNJ
144.36
+0.56%↑
ABBV
175.76
+2.53%↑
LLY
767.18
+1.35%↑
UNH
499.86
+2.58%↑
NVO
85.05
-17.85%↓
JNJ
144.36
+0.56%↑
ABBV
175.76
+2.53%↑
LLY
767.18
+1.35%↑
UNH
499.86
+2.58%↑
NVO
85.05
-17.85%↓
JNJ
144.36
+0.56%↑
ABBV
175.76
+2.53%↑
LLY
767.18
+1.35%↑
UNH
499.86
+2.58%↑
NVO
85.05
-17.85%↓
JNJ
144.36
+0.56%↑
ABBV
175.76
+2.53%↑
LLY
767.18
+1.35%↑
UNH
499.86
+2.58%↑
NVO
85.05
-17.85%↓
JNJ
144.36
+0.56%↑
ABBV
175.76
+2.53%↑
24h
Actual
Mínimo
65.18
Máximo
65.45
Recomendaciones | Compra Fuerte |
---|---|
Estimación a 12 meses | +36.95 upside |
By Trading Central
Confianza
Strong Bearish Evidence
64.31 / 67.085 Soporte y Resistencia
El rendimiento pasado no es un indicador fiable de resultados futuros.
12 nov 2024, 19:55 UTC
AstraZeneca Expands U.S. Investment Plan -- 3rd Update
DJ
Leer
12 nov 2024, 11:02 UTC
AstraZeneca Raises Outlook, Plans U.S. Investment -- Update
DJ
Leer
12 nov 2024, 07:37 UTC
AstraZeneca Raises Outlook on Earnings, Sales Beat
DJ
Leer
10 sept 2024, 09:29 UTC
AstraZeneca Shares Slump After Cancer Drug Misses Key Target
DJ
Leer
18 nov 2024, 10:33 UTC
Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk
DJ
Leer
15 nov 2024, 13:08 UTC
Trump's RFK Pick Weighs on Vaccine Makers -- WSJ
DJ
Leer
15 nov 2024, 10:29 UTC
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
DJ
Leer
12 nov 2024, 15:30 UTC
AstraZeneca Expands U.S. Investment Plan -- 2nd Update
DJ
Leer
12 nov 2024, 13:39 UTC
AstraZeneca's Results Make $80B Revenue Target Look Achievable -- Market Talk
DJ
Leer
12 nov 2024, 10:49 UTC
AstraZeneca Seen With Positive Momentum at Pivotal Period -- Market Talk
DJ
Leer
12 nov 2024, 09:52 UTC
AstraZeneca's New Guidance Could Imply Consensus Upgrades -- Market Talk
DJ
Leer
12 nov 2024, 07:02 UTC
AstraZeneca Had Seen 2024 Core EPS Growth by Mid Teens Percentage Range
DJ
Leer
12 nov 2024, 07:02 UTC
AstraZeneca Sees 2024 Core EPS Growth In High Teens Percentage Range
DJ
Leer
12 nov 2024, 07:02 UTC
AstraZeneca Had Seen 2024 Total Revenue Growth In Mid Teens Percentage Range
DJ
Leer
12 nov 2024, 07:02 UTC
AstraZeneca Sees 2024 Total Revenue Growth In High Teens Percentage Range
DJ
Leer
12 nov 2024, 07:02 UTC
AstraZeneca Raises 2024 View
DJ
Leer
12 nov 2024, 07:01 UTC
Analysts Saw AstraZeneca 3Q Sales at $13.1B
DJ
Leer
12 nov 2024, 07:01 UTC
Analysts Saw AstraZeneca 3Q Core EPS at $2.04
DJ
Leer
12 nov 2024, 07:00 UTC
AstraZeneca PLC 3Q EPS 91c
DJ
Leer
12 nov 2024, 07:00 UTC
AstraZeneca PLC 3Q Net Pft $1.43B
DJ
Leer
12 nov 2024, 07:00 UTC
AstraZeneca PLC 3Q Oper Pft $2.11B
DJ
Leer
7 nov 2024, 08:03 UTC
China Has Detained a Senior AstraZeneca Executive -- Update
DJ
Leer
6 nov 2024, 18:55 UTC
China Has Detained Senior AstraZeneca Executive -- WSJ
DJ
Leer
1 nov 2024, 03:00 UTC
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners -- WSJ
DJ
Leer
31 oct 2024, 19:48 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- Update
DJ
Leer
31 oct 2024, 14:43 UTC
AstraZeneca Probe in China Adds to Concerns for Foreign Businesses -- WSJ
DJ
Leer
12 sept 2024, 17:01 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update
DJ
Leer
12 sept 2024, 11:00 UTC
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
DJ
Leer
10 sept 2024, 13:08 UTC
AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk
DJ
Leer
9 sept 2024, 07:56 UTC
Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk
DJ
Leer
Cambio de precio
By TipRanks
Estimación a 12 meses
Media 89.5 USD 36.95%
Máximo 95 USD
Mínimo 87 USD
De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC ADR Dist en los últimos 3 meses.
By TipRanks
Compra Fuerte
6 ratings
5
Comprar
1
Mantener
0
Vender
De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para AstraZeneca PLC ADR Dist en los últimos 3 meses.
By Trading Central
Corto Plazo
Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Medio plazo
Bearish Evidence
All events are bearish.
Largo Plazo
Bearish Evidence
All events are bearish.
$